The Global Companion Diagnostics Market size was valued at USD 1.96 billion in 2019 and is predicted to reach USD 9.02 billion by 2030, with a CAGR of 14.8% from 2020-2030. Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug for screening the responders and non-responders to that particular drug. It is done in order to identify a patient group that can or cannot be treated with that corresponding drug. CDx helps practitioners to determine the benefits, side effects, and risks associated with the intake of therapeutic drugs, thereby ensuring patient’s safety. The increasing preferences for targeted therapies, growing applications of personalized medicines, higher prevalence of chronic diseases, and increasing incidences of allergies in patients due to side effects of medicines; give rise to development of customized CDx, thereby propagating the growth of global Companion Diagnostics market. Additionally, the benefits offered by CDx test such as cost-effectiveness, high sensitivity, fast and accurate results in less time frames; further escalates the growth of Companion Diagnostics market. Market Segmentations and Scope of the Study: The global companion diagnostics market share has been analyzed based on technology, type, indication, and geography. Based on technology, the market is segmented into Immunohistochemistry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), In Situ Hybridization, and others. Based on indication, the market is divided into Oncology, Neurology, and others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, AsiaPacific, and RoW. Request
for
a
free
sample-
https://www.nextmsc.com/companion-diagnostics-market/request-sample Geographical Analysis North America is expected to dominate the global companion diagnostics market, throughout the forecast period, accounting for the highest market share. This is attributed to wellestablished healthcare infrastructures and medical laboratories, increased investments in R&D activities to develop advanced companion diagnostics, as well as growing preferences towards personalized medicinal therapies in this region. Asia Pacific region is expected to grow substantially in the global companion diagnostics market, with the highest CAGR values, owing to improving healthcare facilities, increased geriatric population prone to cancer & neurological disorders, as well as increasing medical tourism in this region. Inquire
before
buying-
https://www.nextmsc.com/companion-diagnostics-market/inquire-before-buying
Competitive Landscape The companion diagnostics market is highly competitive and consists of various market players. Some of the major market players include Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Foundation Medicine, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Life Technologies Corporation), and Roche (Ventana Medical Systems, Inc.) among others. The key players are employing strategies such as joint ventures for co-developing new products, and acquisitions, in-order to gain stronger position in the companion diagnostics market. For instance, in March 2020, Thermo Fisher Scientific, one of the major players of companion diagnostics market, announced the signing of an agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to co-develop a CDx for cancer. Thermo Fisher's Oncomine Dx Target Test contains 46 cancer-related biomarkers for detection of both DNA and RNA variants. Its workflow features fast turnaround time and lowest sample requirements as compared to conventional oncology tests. In June 2020, Thermo Fisher Scientific, announced that it has extended its strategic partnership with Agios Pharmaceuticals, by signing an extended agreement to co-develop a global CDx for Low-Grade Glioma (LGG) in oncology. This CDx test includes the identification of IDH gene mutations using the Ion Torrent Genexus System and Oncomine Precision Assay test, for LGG patients. About Us: Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics. We carefully analyse the historical data, augment it by constantly keeping an eye on the latest industry trends and estimate the future events to arrive at accurate market forecasts. For more insights, please visit, https://www.nextmsc.com
Tags: #companiondiagnosticsmarketsize
#companiondiagnosticsmarketshare
#companiondiagnosticsmarketanalysis #companiondiagnosticsmarketgrowth